Navigation Links
Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
Date:9/24/2009

SEATTLE and NEW YORK, Sept. 24 /PRNewswire-FirstCall/ -- At its analyst event today, Dendreon Corporation (Nasdaq: DNDN) provided updates on its regulatory and commercialization progress for PROVENGE(R) (sipuleucel-T), the Company's investigational product candidate for men with advanced prostate cancer.

"2009 has been a transformational year for the company as we prepare to commercialize PROVENGE by the middle of next year and make it available to the many men with metastatic castrate-resistant prostate cancer who currently have few appealing treatment options. We are on track to complete the submission of our Biologics License Application (BLA) amendment to the U.S. Food and Drug Administration (FDA) by the middle of November," said Mitchell H. Gold, M.D., president and chief executive officer. "After FDA approval we will implement a deliberate, stepwise launch to ensure the highest quality standards, patient delivery and experience with this completely new approach that could change the way prostate cancer and eventually other cancers are treated."

In addition to this regulatory progress, Dendreon provided the following updates today during its Analyst Day meeting in New York:

Manufacturing and Commercialization Preparation

  • The existing capacity at Dendreon's New Jersey manufacturing facility represents 25 percent of the total future capacity at this facility. After FDA approval, the Company expects to launch PROVENGE from this existing portion of the New Jersey facility in mid-2010 and to continue to make the product available in a gradual stepwise fashion as the Company ramps up to full capacity at this facility.
  • The Company expects to have 48 workstations in production at the New Jersey facility by the
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
3. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
4. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
(Date:10/20/2014)... Oct. 20, 2014  ResMed (NYSE: ... ResMed Data Exchange program, a comprehensive suite of ... (HME) and other health care providers. ... to critical patient information. It integrates valuable sleep ... U-Sleep™ patient management platforms with customers, in-house or ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... this weeks issue of Science,researchers from the National ... in Sweden report an,important discovery about a critical ... plays in replicating DNA in higher organisms,such as ... places us one step closer to understanding the ...
... that HIV patients can live,longer lives, PASADENA, Calif., July ... combination with a second newer agent,has proven to be ... to be published in its July 7th,special HIV/AIDS issue. ... 18,nations and more than 30 centers in the United ...
Cached Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV 2New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV 3
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... ... Washington Hospital Center unveils new state-of-the-art ... include all negative pressure isolation rooms: surfaces made of ... uniquely designed work spaces. The features are designed ...
... N.J., Jan. 8 Medco Health,Solutions, Inc. (NYSE: ... today,reiterated the company,s positive outlook for 2008 at the ... company reiterated its guidance for 2008 GAAP diluted earnings ... that,existed when Medco became a publicly traded company, Medco ...
... carriers , , TUESDAY, Jan. 8 (HealthDay News) -- Not ... show the same risk for developing breast cancer. , ... risk among families carrying the mutations, indicating that the ... factors. , "Risk among carriers varies considerably, and, if ...
... a stage, then proteins would rank among the lead ... These large biological molecules hold many starring roles, and ... genes. They are production powerhouses, regulating the basic processes ... that produce or use energy. Others regulate genes. , ...
... Will Work to Prevent Sudden Cardiac Arrest, ... 8 The Sudden Cardiac Arrest,Association (SCAA) announced ... Minnesota affiliates as it builds a network,of local ... preventing sudden,cardiac arrest (SCA)., The Minnesota SCAA ...
... Groups Will Work to Prevent Sudden Cardiac Arrest Through ... Chapters/Affiliates by This Spring, WASHINGTON, Jan. 8 ... has launched its first 13 local,chapter and affiliate organizations, ... carry out its mission of preventing sudden cardiac,arrest., ...
Cached Medicine News:Health News:Hospital Launches Landmark Project in Emergency Medicine 2Health News:Medco CEO Reiterates Guidance, Positive Outlook for 2008 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 2Health News:BRCA Mutations Don't Raise Breast Cancer Risk Equally 3Health News:Protein power: Researchers trigger insulin production in diabetic mice 2Health News:Protein power: Researchers trigger insulin production in diabetic mice 3Health News:Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates 2Health News:Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates 3Health News:Sudden Cardiac Arrest Association Launches Its First Thirteen Local Chapters/Affiliates 2Health News:Sudden Cardiac Arrest Association Launches Its First Thirteen Local Chapters/Affiliates 3
Ideal for chest procedures....
Male Compression Vests...
Female Compression VEST w/sleeves...
Male Support Brief...
Medicine Products: